Your Coccidiosis Management Partner

BIOPHARM, Research Institute of Biopharmacy and Veterinary Drugs is a research and production facility that offers a range of services. The Company includes four main areas of focus, namely: i) research and development in the area of veterinary drugs, and biotechnological research in poultry production, ii) pharmacological services for the development and manufacturing of veterinary and human drugs, iii) distributional, promotional and publishing activities in the sector of veterinary medicine, and iv) production and sales of veterinary drugs and feedstuffs. These services are managed by specialists and are completed in accordance with GCP, GDP, GLP, GMP, and GPvP rules and regulations relevant to pharmaceutical companies as well as customers from other sectors. The Company is located about 20 km south of Prague, the capital city of the Czech Republic, in Europe.

 

It was in the 1990s that BIOPHARM, Research Institute of Biopharmacy and Veterinary Drugs became one of the leading companies in the global fight against coccidiosis. Coccidiosis is a serious disease that is said to currently still have a global impact on the poultry industry, of around 300 million US Dollars annually. Out of the seven species of coccidia known to infect chickens (Gallus gallus domesticus) there are four species that cause massive economic problems for the industry. In a time where there is a conscious world movement towards a high level of food safety, and in which Europe is leading the campaign for drug-free food production, producers are compelled to drive towards alternative methods of disease control to avoid chemical residues in consumer products.

 

The Company developed two types of live, attenuated (second generation) coccidiosis vaccines for chickens. LIVACOXâ vaccines are a model choice for use in poultry systems since they are non-toxic to the environment, non-target species friendly and effectively easy-to-use products. LIVACOXâ Q is a quadrivalent vaccine for breeders and layers, containing attenuated strains of Eimeria acervulina, E. maxima, E. tenella and E. necatrix. LIVACOXâ T is a trivalent vaccine for broilers, containing attenuated strains of Eimeria acervulina, E. maxima and E. tenella. Both vaccines contain only the coccidian species known to cause economic problems in the respective poultry breeds. The controlled (by lowered pathogenicity) and lowered parasitic infectious pressure imposed on both the birds and the farm environment, makes these vaccines competitively cost-effective and a safe option.

 

LIVACOXâ vaccines not only aid in safeguarding the required standard of flock performance but also upturn the liveability, and help avoid non-uniformity and weight-loss issues. This is achievable without any residues being left in the meat or eggs; hence, there is also no withdrawal period, which in turn is advantageous in broiler and layer operations. The vaccines also benefit the farm in re-populating it with vaccinal coccidia that are non-resistant and sensitive to medicaments, and thus are a progressive choice in rotation programmes. Since only attenuated strains are included in the vaccines, the risks that accompany the application of non-attenuated (virulent) strains are eliminated. Preventative treatment to control for the risk of strong post-vaccination reactions is thus not necessary as it often is for non-attenuated vaccines, and the absence of drug-use in the system reduces the likelihood of resistant oocysts easily re-establishing themselves.

 

LIVACOX® vaccines can be simply administered to young chicks either via drinking water or via coarse-spray, with a one-time vaccination. The host develops a protective, cell-mediated, immune response from 10 days onwards after vaccination. The immune response is then sustained by continuous ‘revaccination’ or boosting by the ingestion of oocysts present in the bird’s environment; resulting in lifelong immunity.

 

The number of vaccinated breeders, broilers and layers is continuously growing worldwide. From BIOPHARM’s experience over the past 20 years of LIVACOXâ use in Africa, Asia, Europe and Latin America, it is evident that despite the varying environmental conditions, the vaccines are a medium to long-term lucrative means of prevention against coccidiosis. They have had a successful and positive contribution to the global struggle against coccidiosis in the poultry industry. With the globally expanding trend to do away with unfavourable drugs used in animal health the future importance of attenuated vaccines is even more notable in the fight against coccidiosis.

Comments are closed.